Quadria Capital is set to acquire a 10% stake in Aragen Life Sciences for about $100 million, valuing the Indian CRDMO at $1.2 billion. The investment will fuel Aragen's expansion, including a new biologics facility, and potentially pave the way for a future IPO. This move underscores the growing interest in Indian CRDMOs amid global pharma supply chain shifts.
